Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

BACKGROUND: Protein kinase inhibitors (PKIs) are currently tested in clinical studies (phase I-III) as an alternative strategy against (recurrent) ovarian cancer. Besides their anti-tumour efficacy, several PKIs have also shown radiosensitizing effects when combined with external beam radiation. Bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindenblatt, Dennis, Terraneo, Nastassja, Pellegrini, Giovanni, Cohrs, Susan, Spycher, Philipp René, Vukovic, David, Béhé, Martin, Schibli, Roger, Grünberg, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156869/
https://www.ncbi.nlm.nih.gov/pubmed/30253737
http://dx.doi.org/10.1186/s12885-018-4836-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156869/
https://www.ncbi.nlm.nih.gov/pubmed/30253737
http://dx.doi.org/10.1186/s12885-018-4836-1

Ejemplares similares